Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Change in Receivables (2016 - 2025)

Historic Change in Receivables for CorMedix (CRMD) over the last 10 years, with Q3 2025 value amounting to $87.3 million.

  • CorMedix's Change in Receivables rose 40794.3% to $87.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $112.9 million, marking a year-over-year increase of 55731.03%. This contributed to the annual value of $51.8 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, CorMedix's Change in Receivables is $87.3 million, which was up 40794.3% from -$11.7 million recorded in Q2 2025.
  • CorMedix's Change in Receivables' 5-year high stood at $87.3 million during Q3 2025, with a 5-year trough of -$11.7 million in Q2 2025.
  • Over the past 4 years, CorMedix's median Change in Receivables value was $1155.0 (recorded in 2022), while the average stood at $10.0 million.
  • The largest annual percentage gain for CorMedix's Change in Receivables in the last 5 years was 182572.89% (2021), contrasted with its biggest fall of 129069.57% (2021).
  • CorMedix's Change in Receivables (Quarter) stood at $47354.0 in 2021, then crashed by 99.07% to $440.0 in 2022, then skyrocketed by 7818794.77% to $34.4 million in 2024, then skyrocketed by 153.67% to $87.3 million in 2025.
  • Its last three reported values are $87.3 million in Q3 2025, -$11.7 million for Q2 2025, and $3.0 million during Q1 2025.